Cocrystal Pharma awarded NIH SBIR grant to further develop influenza inhibitor initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Funding Announcement: Cocrystal Pharma has received a Phase I SBIR award from the NIH, amounting to approximately $500,000.
Research Focus: The funding will support the development of a novel oral antiviral candidate aimed at treating influenza A and B infections.
Project Goals: Cocrystal intends to use the funds to characterize lead candidate molecules that target the influenza polymerase complex.
Significance: This initiative highlights the company's commitment to advancing antiviral treatments in response to influenza viruses.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on COCP
Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.020
Low
10.00
Averages
10.00
High
10.00
Current: 1.020
Low
10.00
Averages
10.00
High
10.00
About COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026
- Clinical Trial Approval: Cocrystal Pharma has received approval from the Emory University Institutional Review Board to initiate a Phase 1b human challenge study for CDI-988, with enrollment expected to begin in Q1 2026, aiming to evaluate its efficacy in preventing and treating norovirus infections.
- Innovative Drug Development: CDI-988 is the first oral broad-spectrum antiviral drug specifically designed to inhibit the 3CL protease of all noroviruses, potentially revolutionizing management in high-risk environments such as hospitals and nursing homes.
- Global Health Impact: With norovirus causing approximately 700 million infections annually, Cocrystal's research addresses this significant global health challenge, which could substantially reduce cases of acute gastroenteritis and associated societal costs.
- Technological Platform Advantage: Leveraging its proprietary structure-based drug discovery platform, Cocrystal aims to rapidly develop novel antiviral agents, and the success of CDI-988 will further solidify its leadership position in the antiviral space, driving future growth for the company.
Continue Reading
Cocrystal Pharma to Present Clinical Progress at NobleCon 21
- Conference Presentation: Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025, showcasing the latest advancements in antiviral treatments.
- Investor Participation: The conference invites interested investors and guests to attend at a discounted rate, aiming to increase visibility and engagement within the small and micro-cap market.
- Webcast Availability: A video of Cocrystal's presentation will be available on December 4 and archived for 90 days on the company's website, ensuring that investors unable to attend live can access critical information.
- Company Background: Cocrystal Pharma is a clinical-stage biotechnology firm focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis, leveraging unique structure-based technologies and Nobel Prize-winning expertise to create first-in-class antiviral drugs.
Continue Reading